Dr Anand Gautam has 25 years of leadership in R&D and innovation strategies in Inflammation/Autoimmune Diseases/Cancer at international biotech and pharmaceutical companies. In addition, Anand has spent over 12 years as an academic in Immunology in prestigious research centers in the UK (PhD at University of London), US (post-doc at Stanford University, California), and Australia (Academic positions at ANU, Canberra & UQ, Brisbane). Before joining Pfizer as a Head of External Science & Innovation, ANZ & Southeast Asia in April 2017, Anand was a Senior Director of R&D Innovation Sourcing at Novo Nordisk, Copenhagen for eight years. Prior to that, Anand was VP of R&D at Progen (Brisbane, Australia), and SVP of External Science & Collaboration at Pharmexa (Denmark). Overall Anand’s aim has been to contribute towards translating meaningful discoveries into innovation that positively impact patients and society.
Dr Gautam has obtained numerous grants to carry out his scientific research, including an NIH grant of USD$2.5 million to work on novel adjuvants for bioterrorism vaccines in 2005; and a Career Development Award from Juvenile Diabetes Foundation International, USA. Anand has published numerous papers in peer-reviewed scientific journals and was awarded a Howard Florey Young Investigator’s Award at John Curtin School of Medical Research in 1996. Anand serves on number committees (e.g. AusBiotech and Bridge Program at MTPconnect, Australia), is a Life Science Queensland Ambassador, and is an Adjunct Professor at The Institute for Molecular Biosciences, University of Queensland.